

Meta-analysis Examining the Usefulness of Angiotensin Receptor blockers for the Prevention of Aortic Root Dilation in Patients With the Marfan Syndrome



Abdullah Al-abcha, MD^a, Yehia Saleh, MD^{a,c}, Mark Mujer, MD^a, Manel Boumegouas, MD^a, Khader Herzallah, MD^a, Lawrenshey Charles, DO^a, Layan Elkhatab, MD^b, Ola Abdelkarim, MD^c, Michael Kehdi, DO^d, and George S. Abela, MD^{d,*}

The Marfan syndrome (MFS) patients are highly predisposed to thoracic aortic aneurysm and/or dissection, with virtually every patient having evidence of aortic disease at some point during their lifetime. We conducted a meta-analysis to investigate the efficacy of angiotensin receptor blockers (ARBs) in slowing down the progression of aortic dilatation in MFS patients. PUBMED, EMBASE, and COCHRANE databases were searched for relevant articles published from inception to February 1, 2020. We included randomized clinical trials evaluating the effect of ARBs on aortic root size in patients with MFS with a follow-up period of at least 2.5 years. Seven studies were included with a total of 1,510 patients. Our analysis demonstrated a significantly smaller change in aortic root and ascending aorta dilation in the ARBs treated group when compared with placebo (mean difference 0.68; 95% confidence interval [CI] −1.31 to −0.04; $p = 0.04$, $I^2 = 94\%$, and mean difference −0.13, 95% CI −0.17 to −0.09; $p < 0.00001$, $I^2 = 0\%$, respectively). ARBs as an add-on therapy to beta-blockers resulted in a significantly smaller change in aortic root dilation when compared with the arm without ARBs (mean difference −2.06, 95% CI −2.54 to −1.58; $p < 0.00001$, $I^2 = 91\%$). However, there was no statistically significant difference in the number of clinical events (aortic complications/surgery) observed in the ARBs arm when compared with placebo (Risk ratio of 1.01, 95% CI 0.74 to 1.38; $p = 0.94$, $I^2 = 0\%$). In conclusion, ARBs therapy is associated with a slower progression of aortic root dilation when compared with placebo and as an addition to beta-blocker therapy.

© 2020 Elsevier Inc. All rights reserved. (Am J Cardiol 2020;128:101–106)

Marfan syndrome (MFS) is an autosomal dominant connective tissue disease and is estimated to affect ≈ 2 to 3 of 10,000 individuals.¹ It results from mutations that involve the FBN1 gene, which controls the production of Fibrillin 1.² Fibrillin 1 is an essential component of all connective tissue in the human body and mutated versions of this glycoprotein result in abnormalities that involve elastic tissues (i.e., lens, skin, heart, and aorta).³ Aortic involvement in MFS includes aneurysm of the ascending, and to a lesser extent descending, and thoracic aorta and often subsequent aortic dissection,⁴ which is the most common cause of mortality in patients with this condition.⁵ Current management strategies of aortic involvement include periodic surveillance with imaging and surgically repairing the aorta when its dilation reaches a certain threshold (≥ 5 cm; growth > 0.5 cm/year; ≥ 4 cm if family history of dissection or contemplated pregnancy).^{6,7} Beta-blockers (BBs) have been used to decrease the rate of aortic root dilation.⁸ Angiotensin Receptor Blockers (ARBs) have

been shown to reduce the progression of aortic root dilation in mice models.⁹ Subsequently, multiple clinical trials studied the effect of ARBs in MFS patients with variable results.^{10–18} Hence, we performed this meta-analysis to evaluate the role of ARBs in MFS patients.

Methods

We conducted a comprehensive review of previous publications of all relevant studies through February 2020. We searched PUBMED, EMBASE, and COCHRANE databases. We included studies that met our criteria of: (1) the study was a randomized clinical trial published in a peer-reviewed journal, (2) the study evaluated the effect of ARBs on patients with MFS, (3) the study reported the mean difference of aortic root size with time, (4) the study followed the patients for at least 2.5 years. The meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.¹⁹ The search included the following keywords: ARBs or losartan or irbesartan; MFS; Aortic dilation or Aortic dissection. Two authors (AA and YS) independently reviewed the search results, extracted potential articles, and assessed their eligibility. The Cochrane Collaboration risk-of-bias tool was used by two different authors (AA and YS) to assess the quality of randomized clinical trials (RCTs). The primary endpoint of this meta-analysis was mean change in aortic root size. We collected

^aDepartment of Internal Medicine, Michigan State University, East Lansing, Michigan; ^bDepartment of Internal Medicine, Henry Ford Hospital, Detroit, Michigan; ^cDepartment of Cardiology, Alexandria University, Egypt; and ^dDepartment of Internal Medicine, Division of Cardiology, Michigan State University, East Lansing, Michigan. Manuscript received March 2, 2020; revised manuscript received and accepted April 20, 2020.

See page 105 for disclosure information.

*Corresponding author: Tel: +15173531754; fax: +15173534978.

E-mail address: abela@msu.edu (G.S. Abela).

the following characteristics of each study: first author's name, year of publication, single vs multicenter, number of participants in each arm, type of control arm, follow up duration, imaging modality, mean age, and mean aortic root size at baseline. Secondary outcomes included clinical events and change in ascending aorta diameter. Clinical events included aortic dissection, aortic surgery, cardiac mortality, cardiovascular-related mortality, and all-cause mortality. Statistical analysis was conducted using Review Manager (RevMan), version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark). The Mantel-Haenszel random-effects models were used to estimate the mean difference and the corresponding 95% confidence intervals (CIs). Two-sided p values of <0.05 were considered as statistical significance. I^2 statistics were used to assess statistical heterogeneity. Sensitivity analysis was done with the exclusion of one to two trials to evaluate heterogeneity. A funnel plot was used to assess publication bias.

Results

Seven RCTs were included with a total of 1,510 patients (Figure 1). Characteristics of included studies and patients are described in Tables 1 and 2. A pooled analysis of the data had a significantly smaller change in aortic root dilation in the ARBs group when compared with placebo (mean difference -0.68 ; 95% confidence interval [CI], -1.31 to -0.04 ; $p = 0.04$, $I^2 = 94\%$; Figure 2). Sensitivity analysis showed that heterogeneity was the lowest ($I^2 = 0\%$) when Chiu et al¹³ and Groenink et al¹² were excluded. Subgroup analysis of the clinical trials that compared ARBs as an add-on therapy to BBs demonstrated that the addition of ARBs to BBs results in a significantly smaller change in aortic root dilation when compared with BBs-alone (mean difference -2.06 , 95% CI -2.54 to -1.58 ; $p < 0.00001$, $I^2 = 91\%$; Figure 3). When ARBs were compared head to head with BBs, we found a smaller change in aortic root dilation in the BBs-alone arm (mean difference 0.06 , 95% CI 0.05 to 0.07 ; $p < 0.00001$, $I^2 = 0\%$) (Figure 4).

There was no statistically significant difference in the number of clinical events observed in the ARBs arm when compared with placebo (Risk ratio of 1.01 , 95% CI 0.74 to 1.38 ; $p = 0.94$, $I^2 = 0\%$; Figure 5), or BBs (Risk ratio of 1.20 , 95% CI 0.48 to 2.98 ; $p = 0.69$, $I^2 = 64\%$; Figure 6). There was a statistically significant smaller change in the diameter of the ascending aorta in the ARBs arm when




Figure 1. The preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram.

compared with placebo (mean difference -0.13 , 95% CI -0.17 to -0.09 ; $p < 0.00001$, $I^2 = 0\%$; Figure 7). However, BBs-alone had a significantly lower rate of change in ascending aorta diameter when compared with ARBs-alone (mean difference 0.05 , 95% CI 0.04 to 0.06 ; $p < 0.00001$, $I^2 = 0\%$; Figure 8). Funnel plot was used to assess for publication bias (Figure 9).

Discussion

Since the 1970s, BBs had shown efficacy in slowing down the progression of thoracic aortic disease in animal models.²⁰ Subsequently in 1994, Shores et al, randomized 70 patients diagnosed with MFS to propranolol versus placebo. After 10 years of follow-up, the propranolol arm demonstrated a significant reduction in aortic root growth and the development of aortic complications.²¹ Subsequent observational reports demonstrated contradicting evidence of BBs in slowing down the progression of aortic dilatation.^{22–24} Although the currently available evidence does not provide a strong rationale for the β -adrenergic

Table 1
Baseline characteristics of studies included in the meta-analysis

Study (year)	Number of centers	Arbs group (N)	Control group (N)	Arbs arm	Control arm	Follow-up duration (years)	Imaging modality used for follow-up
Mullen (2020)	Multi	104	88	Irbesartan	Placebo	5	TTE
Teixido-Tura (2018)	Multi	64	64	Losartan	Atenolol	6	CMR
Muino-Mosquera (2017)	Single	12	10	Losartan	Placebo	3	TTE
Milleron (2015)	Multi	151	148	Losartan	Placebo	3.5	TTE
Lacro (2014)	Multi	305	303	Losartan	Atenolol	3	TTE
Chiu (2013)	Single	15	13	Losartan	Atenolol, Propranolol	3	TTE
Groenink (2013)	Multi	116	117	Losartan	Usual care	3	CMR

Abbreviations: ARBs = angiotensin receptor blockers; CMR = cardiac magnetic resonance imaging; TTE = transthoracic echocardiography.

Table 2
Baseline characteristics and outcomes of studies included in the meta-analysis

Study (year)	Age, years (mean)	Male (%)	Presence of causal fbn1 mutation (%)	Baseline z-score	Baseline aortic root diameter, mm (mean)	Change in absolute root diameter, mm (mean)	P-value of the change in root diameter	Prior beta-blockers (%)
Mullen (2020)							0.035	
A, N = 104	18	45	NA	3.2	34.4	0.15		54
C, N = 88	18	52	NA	32.3	34.4	0.05		59
Teixido-Tura (2018)							0.754	
A, N = 64	25.6	35.9	83.3	3.2	35.7	0.4		0
C, N = 64	23.8	46.9	80	3.2	30.9	0.4		0
Muino-Mosquera (2017)							0.768	
A, N = 12	36.83	33.3	NA	3.57	25	1		NA
C, N = 10	35.4	60.1	NA	3.48	25.8	1		NA
Milleron (2015)							0.36	
A, N = 151	30.9	44	78.1	3.74	39.1	0.44		86
C, N = 148	28.9	41	77.7	3.69	39.2	0.51		80
Lacro (2014)							0.20	
A, N = 305	11.0	61	31	1.8	34	0.75		57
C, N = 303	11.5	59	29	1.7	34	0.69		56
Chiu (2013)							0.03	
A, N = 15	12.5	33.3	NA	3.79	21.8	0.3		100
C, N = 13	13.7	46.1	NA	3.26	20	2.7		100
Groenink (2013)							0.014	
A, N = 116	36.8	59.5	74.8	3.9	44.8	0.77		75
C, N = 117	38.3	47	88.2	3.8	43.7	1.35		70.10
Total							NA	
A, N = 767	24.5	44.6	66.8	NA	33.5	0.54		62
C, N = 743	24.2	50.3	68.7	NA	32	0.96		60.8

Abbreviations: A = angiotensin receptor blockers arm; C = control arm; NA = not available.




Figure 2. Forest plot of change in aortic diameter in ARBs versus placebo groups.




Figure 3. Forest plot of change in aortic diameter in ARBs as an add-on to beta-blockers vs beta-blockers alone.




Figure 4. Forest plot of change in aortic diameter in ARBs alone vs B-blocker alone.




Figure 5. Forest plot of clinical events in ARBs vs placebo.




Figure 6. Forest plot of clinical events in ARBs alone vs B-blockers alone.




Figure 7. Forest plot of change in ascending aortic diameter in ARBs vs placebo.




Figure 8. Forest plot of change in ascending aortic diameter in ARBs alone vs B-blockers alone.

blockade, it is still considered by many physicians to be the “gold standard.” The 2010 American Heart Association/American College of Cardiology guidelines stated that “For patients with thoracic aortic aneurysm, it is reasonable to reduce blood pressure with BBs (Class IIA, level of evidence B).”⁸ This recommendation concurs with the 2017 hypertension guidelines, which recommend BBs as the preferred antihypertensive drug class in patients with hypertension and thoracic aortic disease.²⁵

The discovery of the Transforming Growth Factor pathway unraveled another avenue in the management of MFS. The Transforming Growth Factor pathway can be blocked by ARBs, precluding this finding of paramount significance as it provided the first new therapeutic option in over 2 decades.⁹ In a small cohort study that included 18 pediatric patients, the addition of ARBs to BBs therapy in patients

with MFS significantly slowed the rate of progressive aortic root dilation.²⁶ Afterward, off label losartan became widely used in MFS patients and several RCTs were conducted. In a multicenter RCT that included 233 participants comparing losartan with no additional treatment, aortic root dilatation rate after 3.1 years was significantly lower in the losartan group than with conventional treatment (0.77 vs 1.35 mm). However, no significant differences in aortic dissection, elective aortic surgery or cardiovascular death between the groups were demonstrated (10 vs 11 events).¹² Since irbesartan is a selective angiotensin type-1 receptor blocker with greater bioavailability, a longer half-life, and more powerful antihypertensive effects than losartan, Mullen et al randomized 192 participants to irbesartan or placebo. At 5 years follow up the mean rate of aortic root dilatation was 0.53 mm/year in the irbesartan group




Figure 9. Funnel plot of the mean change in aortic root size.

compared with 0.74 mm/year in the placebo group ($p=0.030$). There were 5 aortic surgical procedures in the irbesartan group and 4 in the placebo group.¹⁸ Although the study provided valuable information, nonetheless there were several limitations. The study did not achieve the needed power due to low numbers and high drop-out rate. Furthermore, 56% of the patients were on BBs, the study was underpowered to perform meaningful subgroup analysis to investigate the role of ARBs in addition to BBs. In order to evaluate the effect of losartan in combination with BBs, Chiu et al randomized 28 patients with MFS on BBs to receive losartan as add on therapy. After a 35 month follow-up period, the losartan group had a significant reduction in the aortic root dilation.¹³ In contrast, a similar design study by Mosquera et al that randomized 22 patients on BBs therapy to either losartan and placebo, did not have additional effect with losartan on inhibiting aortic growth at 3-year follow up.¹⁶ In our meta-analysis, there was a significantly smaller change in aortic root and ascending aorta dilation in the ARBs group when compared with placebo (Figures 2 and 7). Subgroup analysis of the clinical trials that compared ARBs as an add-on therapy to BBs demonstrated that the addition of ARBs to BBs results in a significantly smaller change in aortic root dilation (Figure 3). Yet, there was no statistically significant difference in the number of clinical events observed in the ARBs arm when compared with the placebo. Given the rarity of the clinical events in MFS, we hypothesize that the trials conducted to date might not have been sufficiently powered to detect differences in clinical outcomes. However, although most trials aimed for the maximum tolerated dose of ARBs, it was still relatively a low dose in comparison to the doses used in animal trials.⁹

Two trials evaluated BBs and losartan head to head. The first was a multicenter randomized trial comparing losartan with atenolol in 608 patients with MFS. There was no

significant difference in the rate of aortic root dilation between the 2 groups over 3 years. Moreover, although 10 patients in the BB arm vs 19 patients in the losartan arm had aortic complications/surgery, it did not reach statistical significance between the 2 groups ($p=0.10$).¹¹ The second, a study that included 128 participants randomized to atenolol versus losartan followed for 6.7 years, found no significant difference between the groups. Additionally, 9 events (14.1%) occurred in the losartan group and 12 (18.8%) in the atenolol group, which was also statistically nonsignificant.¹⁰ In our meta-analysis, the subgroup analysis comparing ARBs to BBs demonstrated a statistically significant smaller change in aortic root and ascending aorta dilation in the BBs arm (Figures 4, and 8). However, there was no significant difference in the number of clinical events (Figure 6).

In conclusion, this meta-analysis demonstrated that the use of ARBs in MFS patients can significantly slow down the progression of aortic root dilatation. Subgroup analysis demonstrated that BBs-alone was associated with a significantly smaller change in aortic root diameter when compared with ARBs-alone therapy. However, ARBs as an add on therapy to BBs had significantly slower progression of aortic root dilation in comparison to placebo. There was no significant difference in aortic complications/surgery when using ARBs.

Disclosure

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

1. Magotteaux S, Bulk S, Farhat N, Sakalihasan N, Defraigne JO, Seghaye MC. Marfan syndrome in childhood and adolescence. *Rev Med Liege* 2016;71(7-8):342-348.

2. Kumar A, Agarwal S. Marfan syndrome: an eyesight of syndrome. *Meta Gene* 2014;2:96–105.
3. Sakai LY, Keene DR, Renard M, De Backer J. FBN1: the disease-causing gene for Marfan syndrome and other genetic disorders. *Gene* 2016;591(1):279–291.
4. von Kodolitsch Y, Spielmann RP, Nienaber CA. Acute and chronic aortic diseases in Marfan syndrome and arterial hypertension—a comparison of anatomy, clinical aspects and prognosis. *Z Kardiol* 1995;84(7):542–552.
5. Groth KA, Stochholm K, Hove H, Andersen NH, Gravholt CH. Causes of mortality in the marfan syndrome (from a nationwide register study). *Am J Cardiol* 2018;122(7):1231–1235.
6. Goldfinger JZ, Halperin JL, Marin ML, Stewart AS, Eagle KA, Fuster V. Thoracic aortic aneurysm and dissection. *J Am Coll Cardiol* 2014;64(16):1725–1739.
7. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, Allmen RS, Vrints CJ. 2014 ESC guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The task force for the diagnosis and treatment of aortic diseases of the European Society of Cardiology (ESC). *Eur Heart J* 2014;35(41):2873–2926.
8. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr., Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. *Circulation* 2010;121(13):e266–e369.
9. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. *Science* 2006;312(5770):117–121.
10. Teixeira-Tura G, Forteza A, Rodriguez-Palomares J, Gonzalez Mirelis J, Gutierrez L, Sanchez V, Ibanez B, Garcia-Dorado D, Evangelista A. Losartan versus atenolol for prevention of aortic dilation in patients with Marfan syndrome. *J Am Coll Cardiol* 2018;72(14):1613–1618.
11. Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, Pearson GD, Selamet Tierney ES, Levine JC, Atz AM, Benson DW, Braverman AC, Chen S, De Backer J, Gelb BD, Grossfeld PD, Klein GL, Lai WW, Liou A, Loeys BL, Markham LW, Olson AK, Paridon SM, Pemberton VL, Pierpont ME, Pyeritz RE, Radojewski E, Roman MJ, Sharkey AM, Stylianou MP, Wechsler SB, Young LT, Mahony L. Atenolol versus losartan in children and young adults with Marfan's syndrome. *N Engl J Med* 2014;371(22):2061–2071.
12. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, Scholte AJ, van den Berg MP, Spijkerboer AM, Marquering HA, Zwinderman AH, Mulder BJ. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. *Eur Heart J* 2013;34(45):3491–3500.
13. Chiu HH, Wu MH, Wang JK, Lu CW, Chiu SN, Chen CA, Lin MT, Hu FC. Losartan added to beta-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. *Mayo Clin Proc* 2013;88(3):271–276.
14. Milleron O, Arnoult F, Ropers J, Aegerter P, Detaint D, Delorme G, Attias D, Tubach F, Dupuis-Girod S, Plauchu H, Barthelet M, Sassolas F, Pangaud N, Naudion S, Thomas-Chabaneix J, Dulac Y, Edouard T, Wolf JE, Faivre L, Odent S, Basquin A, Habib G, Collignon P, Boileau C, Jondeau G. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. *Eur Heart J* 2015;36(32):2160–2166.
15. Bhatt AB, Buck JS, Zuflacht JP, Milian J, Kadivar S, Gauvreau K, Singh MN, Creager MA. Distinct effects of losartan and atenolol on vascular stiffness in Marfan syndrome. *Vasc Med* 2015;20(4):317–325.
16. Muino-Mosquera L, De Nobele S, Devos D, Campens L, De Paepe A, De Backer J. Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial. *Acta Cardiol* 2017;72(6):616–624.
17. Elbadawi A, Omer MA, Elgendy IY, Abuzaid A, Mohamed AH, Rai D, Saad M, Mentias A, Rezaq A, Kamal D, Khalife W, London B, Morsy M. Losartan for preventing aortic root dilatation in patients with Marfan syndrome: a meta-analysis of randomized trials. *Cardiol Ther* 2019;8(2):365–372.
18. Mullen M, Jin XY, Child A, Stuart AG, Dodd M, Aragon-Martin JA, Gaze D, Kiotseoglou A, Yuan L, Hu J, Foley C, Van Dyck L, Knight R, Clayton T, Swan L, Thomson JDR, Erdem G, Crossman D, Flather M. Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial. *Lancet* 2020;394(10216):2263–2270.
19. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.
20. Simpson CF, Kling JM, Palmer RF. Beta-aminopropionitrile-induced dissecting aneurysms of turkeys: treatment with propranolol. *Toxicol Appl Pharmacol* 1970;16(1):143–153.
21. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. *N Engl J Med* 1994;330(19):1335–1341.
22. Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman MJ, Boxer M, Devereux RB, Tsipouras P. Life expectancy in the Marfan syndrome. *Am J Cardiol* 1995;75(2):157–160.
23. Salim MA, Alpert BS, Ward JC, Pyeritz RE. Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. *Am J Cardiol* 1994;74(6):629–633.
24. Ladouceur M, Fermanian C, Lupoglazoff JM, Edouard T, Dulac Y, Acar P, Magnier S, Jondeau G. Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. *Am J Cardiol* 2007;99(3):406–409.
25. Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbigele B, Smith SC Jr., Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr., Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. *Circulation* 2018;138(17):e426–e483.
26. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. *N Engl J Med* 2008;358(26):2787–2795.